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Abstract 
In the pathogenesis of monoclonal gammopathies (MG), namely in multiple myeloma (MM), 
the bone marrow microenvironment displays a critical role. As there is accumulating evidence 
supporting a link between obesity and MM, it is possible that this association is made through 
altered adipokines secretion levels. Whereas these hormones are important in several 
physiologic functions, there are studies showing that they also participate in the 
carcinogenesis process of some solid tumors. However, adipokine's role in hematological 
malignancies is poorly understood. 
We studied the role of adiponectin, leptin, resistin, MCP-1, and TNF-α in patients with MG, 
by correlating the peripheral blood (PB) and bone marrow (BM) levels of these adipokines 
with patient's clinical and laboratorial characteristics, as well with prognostic factors. 
A total of 111 MG patients - 52 with monoclonal gammopathy of undetermined significance 
(MGUS), 20 with smoldering multiple myeloma (sMM) and 39 with symptomatic MM - and 
69 non-neoplastic controls were included in this study. PB and BM adipokines levels were 
accessed using ELISA commercial kits. Comparison between groups of patients and controls 
was performed using nonparametric Mann-Whitney  test.  Survival analysis was made by the 
Kaplan-Meier method.    
Our results show an increase in leptin and resistin PB levels in MG patients compared with 
controls. In MGUS patients we observe the highest adiponectin PB and BM levels, and in 
symptomatic MM the lowest, having sMM patients an intermediate value. On the other hand, 
leptin levels were higher in the PB and BM of sMM individuals when comparing with MGUS 
and symptomatic MM. MCP-1 tended for higher levels in patients in the later stages of the 
disease. sMM was also associated with higher PB TNF-α levels. Results from BM of patients 
were somewhat overlapping with those from the PB. 
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When considering laboratorial characteristics, adipokine secretion seems to be dependent of 
the type of heavy chain produced. Light chain symptomatic MM patients were associated with 
the higher levels of adiponectin and TNF-α, as well with the lower levels of leptin and 
resistin, when compared with IgG and IgA symptomatic MM patients. In what concerns the 
type of light chain that is produced, MGUS individuals producing κ light chains, presented 
higher BM levels of MCP-1. 
Additionally, the presence of hypercalcemia and bone lesions in symptomatic MM patients, is 
associated with higher PB and BM leptin levels. Also MCP-1 levels in the BM of patients 
who had anemia were higher than those who did not have. According to the ISS, stage III 
patients, seem to have higher PB levels of resistin than those in stage I. However they show 
the inverse tendency in the BM. Finally, higher levels of PB adiponectin and BM leptin were 
associated with decreased overall survival. 
These results suggest that, adipokines may be involved in MG, namely in MM, by creating a 
pro-inflammatory BM microenvironment, that could contribute to the carcinogenesis process, 
and by participating in the immunological changes underlying the pathogenesis of MM. As 
MM remains an incurable disease, better understanding of the MM pathogenesis, is of critical 
importance to create new therapeutic approaches and improve the patient's prognosis. 
Keywords 
Monoclonal Gammopathy; Multiple Myeloma; Adipokines; Microenvironment; Prognosis 
 
  
The Role Of Adipokines In Monoclonal Gammopathies 
 
5 
 
Resumo 
Na patogénese das gamapatias monoclonais (GM), nomeadamente no mieloma múltiplo 
(MM), o microambiente da medula óssea exibe um papel importante. Com a evidência 
acumulada que suporta uma ligação entre obesidade e o MM, é possível que esta associação 
seja feita através de uma alteração dos níveis de secreção das adipocitocinas. Enquanto estas 
hormonas são importantes em diversas funções fisiológicas, existem estudos que mostram que 
estas também participam no processo de carcinogénese de alguns tumores sólidos. No 
entanto, o papel das adipocitocinas em neoplasias hematológicas é pouco compreendido. 
Nós estudámos o papel da adiponectina, leptina, resistina, MCP-1 e TNF-α em doentes com 
GM, correlacionando os níveis de adipocitocinas no sangue periférico (SP) e medula óssea 
(MO), com as características clínicas e laboratoriais dos doentes, bem como com factores 
prognósticos. 
Um total de 111 doentes com GM - 52 com gamapatia monoclonal de significado 
indeterminado (MGUS), 20 com mieloma múltiplo indolente (sMM) e 39 com MM 
sintomático - e 69 controlos não neoplásicos foram incluídos neste estudo. Os níveis de 
adipocitocinas no SP e MO foram quantificados através de kits comerciais de ELISA. A 
comparação entre grupos de doentes e controlos foi realizada através do teste não paramétrico 
de Mann-Whitney. A análise de sobrevivência  foi conseguida pelo método de Kaplan-Meier.    
Os nossos resultados mostram um aumento dos níveis de leptina e resistina no SP dos doentes 
com GM, comparado com os controlos. Observámos nos doentes com MGUS níveis maiores 
de adiponectina no SP e na MO, e menores nos doentes com MM sintomáticos, tendo os 
doentes com sMM um valor intermédio. Por outro lado, os níveis de leptina no SP e MO de 
doentes com sMM estavam elevados, quando comparados com MGUS e MM sintomático. 
MCP-1 tendeu para níveis superiores em doentes nas fases mais tardias da doença. sMM 
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também estava associado a níveis superiores de TNF-α no SP. Os resultados da MO dos 
doentes eram, de algum modo, sobreponíveis aos encontrados no SP. 
Quando consideradas características laboratoriais, a secreção de adipocitocinas parece ser 
dependente do tipo de cadeia pesada produzida. Doentes com MM sintomático de cadeias 
leves, estavam associados a maiores níveis de adiponectina e TNF-α, bem como a menores 
níveis de leptina e resistina, comparativamente ao doentes com MM sintomático IgG e IgA. 
No que diz respeito ao tipo de cadeia leve produzida, os indivíduos com MGUS produtores de 
cadeias leves κ, apresentaram níveis superiores de MCP-1 na MO. 
Adicionalmente, a presença de hipercalcémia e lesões ósseas em doentes com MM 
sintomático, está associada a níveis superiores de leptina no SP e MO. Também, os níveis de 
MCP-1 na MO dos doentes com anemia, estavam mais altos dos que os que não tinham. De 
acordo com a ISS, doentes em estádio III, parecem ter níveis superiores de resistina no SP em 
relação aos do estádio I. No entanto, eles mostram a tendência inversa na MO. Finalmente, 
níveis elevados de adiponectina no SP e de leptina na MO, foram associados com diminuição 
da sobrevivência geral. 
Estes resultados sugerem que, as adipocitocinas podem estar envolvidas nas GM, 
nomeadamente no MM, ao criarem um estado pró-inflamatório no microambiente da MO, que 
poderá contribuir para o processo de carcinogénese, e ao participarem nas alterações 
imunológicas subjacentes à patogénese do MM. Como o MM permanece uma doença 
incurável, uma melhor compreensão da patogénese do MM, é de grande importância para 
criar novas abordagens terapêuticas e melhorar o prognóstico dos doentes.  
Palavras-chave 
Gamapatia monoclonal; Mieloma Múltiplo; Adipocitocinas; Microambiente; Prognóstico  
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1. Introduction 
Monoclonal gammopathies (MG) are a condition that arises from an overproduction of one 
plasma or lymphoplasmacytic cell clone, which is recognized through serum or urine 
electrophoresis that detects the abnormal amounts of immunoglobulins  produced by those 
cells (M-protein). MG that derive from plasma cells include pre-malignant and malignant 
conditions such as monoclonal gammopathy of undetermined significance (MGUS) and 
multiple myeloma (MM), respectively 
(1)
.  
MGUS is a plasma cell derived pre-malignant disorder, affecting at least 3% of the population 
above the age of 50, that is clinically defined by the presence of a serum M-protein inferior to 
3g/dL, bone marrow plasma cells lower than 10% and absence of end-organ damage related 
symptoms 
(2–4)
. MM cases are usually preceded by MGUS, which is considered the first 
pathogenic step into this plasma cell malignancy
(5,6)
. MGUS has a 1% annual risk of 
progression to MM or related disorder
 (7)
. 
MM is a malignant plasma cell disorder that represents approximately 10% of all 
hematological cancers and 1% of neoplastic diseases, with an annual age-adjusted incidence 
of 5.6 cases per 100,000 persons. The median age of diagnosis is 70 years, and it's two times 
more frequent in African Americans compared with Caucasians, and slightly more common 
in males than females 
(5,8,9)
. The disease is defined by the following three criteria: presence of 
a serum M-protein superior to 3g/dL; bone marrow plasma cells higher than 10% and 
presence of end-organ damage related symptoms, defined as CRAB symptoms 
(hypercalcemia, renal insufficiency, anemia and lytic bone lesions). When the patient has no 
end-organ damage related symptoms, the disorder is classified as smoldering or asymptomatic 
multiple myeloma (sMM) 
(7,10)
. sMM has an annual risk of progression to MM of 10% in the 
first five years, 3% in the following five years, and then 1% 
(4)
. 
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Relatively to the pathogenesis of MM, it has been proposed a model that involves two 
different, but perhaps overlapping, pathways. One, with a high incidence of gene 
translocations of the immunoglobulin heavy chain (IgH) gene, leading to nonhyperdiploid 
tumors, and another with multiple trisomies, leading to hyperdiploid tumors 
(11)
. Primary 
translocations occurs in the germinal center B cells, and they lead to a deregulation of a 
variety of oncogenes such as cyclin D1 or D3, which leaves the cells more susceptible to 
proliferative stimuli, resulting in the expansion of a certain clone. Secondary translocations 
are responsible for the progression to MM, and occur later in the disease. They usually 
involve activating mutations of c-MYC, N- and K-RAS oncogenes 
(6,11)
. 
Besides the genetic and epigenetic changes, also the bone marrow microenvironment (BMM) 
displays a major role in the pathogenesis of MM. The BMM includes extracellular matrix 
(ECM) proteins and various cell types such as bone marrow stromal cells (BMSCs), 
endothelial cells, osteoclasts and osteoblasts 
(12)
. Homing of MM cells to the bone marrow 
mediated through the release of specific chemokines, such as monocyte chemotactic proteins 
1, 2 and 3 (MCP-1, -2 and -3), and adhesion molecules, such as syndecan-1 and very late 
antigen 4 (VLA-4), leads to an interaction of the tumor cells with the BMSCs and ECM 
proteins 
(11,13)
. This interaction promotes activation of proliferative/anti-apoptotic signaling 
pathways (e.g JAK/STAT3, RAS/RAF/MAPK, and  PI3K/AKT/mTOR) and  secretion of 
various types of cytokines such as interleukin 6 (IL-6), insulin-like growth factor 1 (IGF-1), 
vascular endothelial growth factor (VEGF), tumor necrosis factor α (TNF-α) and receptor 
activator of NF-κB ligand (RANKL). Such interactions are crucial for tumor cell growth and 
proliferation, angiogenesis, bone destruction, resistance to pro-apoptotic stimuli (including 
conventional therapies) and metastasis 
(11,12,14)
. Another cell type that also belongs to the bone 
marrow, and it is often forgotten, is the adipocyte. 
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The adipose tissue, not only serves as an energy storage depot and mechanical barrier, but it 
also acts as an active endocrine organ through the secretion of adipokines 
(15)
, which play an 
important role in energy balance, insulin-sensitivity, lipid metabolism, blood pressure, 
angiogenesis, hemostasis, immunity, inflammation and acute-phase response 
(16)
. These 
hormones are produced predominantly by adipocytes of white adipose tissue (e.g. leptin and 
adiponectin) in adipocytes and other tissues (e.g  TNF-α, and IL-6) and in adipocytes and 
others adipose tissue cells (e.g resistin) 
(17)
.  
The role of adipokines in inflammation has been extensively studied due to its implications in 
obesity-related pathologies. They have pro-inflammatory (resistin, TNF-α, MCP-1) and  anti-
inflammatory properties (adiponectin), or play a role in inflammation in accordance to its 
levels and tissue's resistance (leptin) 
(18)
. Furthermore, there is strong evidence that adipose 
tissue expansion is on the basis of several obesity related disorders such as metabolic 
syndrome, hypertension, atherosclerosis, chronic kidney disease diabetes, respiratory 
disorders and, more recently, cancer 
(19)
. One mechanism behind this relationship is the 
crosstalk between adipocytes and the immune system through deregulation of the adipokines 
secretion 
(20,21)
. In fact, obesity is characterized by a state of low-grade inflammation 
(16)
, with 
secretion of high levels of pro-inflammatory adipokines and cytokines, at least in part due to 
an increased number of resident macrophages in the adipose tissue
 (22)
. Whereas pro-
inflammatory adipokines are overproduced in obesity, adiponectin production is reduced 
(15)
. 
The role of adipokines in cancer is being studied to clarify their participation in the 
carcinogenesis process, given the relationship between obesity and certain types of cancer 
such as breast, endometrial and colon cancer 
(17)
. A recent review also linked obesity with the 
risk for hematological malignancies such as leukemia, lymphoma and multiple myeloma 
(23)
. 
In vitro studies on different cancer cell lines using leptin showed that this adipokine had 
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various effects such as increased cell proliferation, growth, transformation, invasion, and 
apoptosis suppression
 (17)
, suggesting a role of this hormone in the carcinogenesis process. 
Moreover, accumulating evidence suggests that adiponectin can have anti-neoplastic effects 
by acting directly on cancer cells, and perhaps indirectly by modulating insulin-sensitivity at 
the target tissue site regulating inflammatory responses and influencing tumor angiogenesis 
(24)
. The influence of other adipokines is not so widely studied. 
In MM, following the compelling evidence that obesity is positively related with incidence 
and mortality of this malignancy 
(9,25,26)
, some studies aiming to discover the role of 
adipokines in the pathogenesis of MM have been undertaken. As the mechanisms behind the 
observed association between obesity and MM are not very clear, only now the focus has 
started to change to the adipocyte. As stated above, the adipocyte is a bone marrow cell that is 
often forgotten. The number of adipocytes increases with age, resulting in adipocyte deposits 
occupying up to 70% of the bone marrow cavity in elderly persons 
(27)
. It has been shown that 
increased visceral adiposity is associated with more bone marrow fat, despite no correlation 
between bone marrow fat and body mass index (BMI), subcutaneous or total abdominal 
adipose tissue 
(28)
. Knowing that MM median age of diagnosis is 70 years and giving the 
positive association with obesity, it is plausible to think that bone marrow adipocytes may 
interact with MM cells, namely through deregulation of adipokines production. 
However the role of the adipokines in MM, and in all obesity-related cancers is poorly 
understood. A better understanding of its role in the pathogenesis of MM may provide a new 
approach to this malignancy, prevent clinical MM, design new strategies of treatment and 
improve prognosis classification. 
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1.1 Aims 
In the present study, we aim to explore the role of pro- and anti-inflammatory adipokines, 
namely adiponectin, leptin, resistin, MCP-1 and TNF-α in the pathogenesis of MG, namely in 
MGUS, sMM and symptomatic MM, and correlate its levels with patient's clinical and 
laboratorial characteristics, as well with prognostic factors. 
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2. Materials and Methods 
 
 
2.1. Ethical statement 
The present study was conducted in accordance with the Helsinki declaration. The Ethics 
Committee of Faculty of Medicine of University of Coimbra (Coimbra, Portugal) approved 
all research procedures. All participants provided their informed consent for participation in 
this study prior to enrollment. 
 
2.2. Study population 
To fulfill our objectives, we studied a total of 111 MG patients followed in the Hematology 
Service of Centro Hospitalar e Universitário de Coimbra (CHUC): 52 were patients with 
MGUS, 20 with sMM and 39 with symptomatic MM. We also studied 69 non-neoplastic 
controls with mild cognitive impairment followed in the Neurology Service of CHUC for 
Alzheimer's disease screening (they did not had any kind of dementia). We collected 
demographic characteristics for patients and controls, and recorded patient's clinical 
characteristics, namely the type of paraprotein, ISS stage and CRAB symptoms. We also 
maintained patient's follow-up in order to collect survival data and correlate it with adipokines 
levels. 
 
2.3 Evaluation of adipokines levels in MG patients and controls 
We analyzed samples obtained from MG patients and control's peripheral blood (PB), and 
from bone marrow (BM) of MG patients, that were collected before any therapeutic approach. 
PB and BM samples were collected into EDTA tubes, and were centrifuged for 10 minutes at 
1000 g. After this, samples were immediately aliquoted and stored at -80ºC.  
PB and BM adiponectin, leptin and resistin levels were measured using ELISA sets from 
R&D Systems
®
 (human Adiponectin Duoset
®
 ELISA; human Leptin Duoset
®
 ELISA; human 
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Resistin Duoset
®
 ELISA). The levels of MCP-1 and TNF-α were also measured using ELISA 
sets  from BD Biosciences (BD OptEIA
™
 Human MCP-1 ELISA Set; BD OptEIA
™
 Human 
TNF-α ELISA Set). We did not analyze MCP-1 and TNF-α levels in the control's PB 
samples. 
2.4 Statistical analysis 
Statistical analysis of the data was performed with IBM
®
 SPSS
®
 Statistics Version 22. We 
performed descriptive analysis of the characteristics of patients and controls. PB and BM 
adipokines levels are presented in median and interquartile range (IQR), and presented as 
whisker and box plots. Comparison between cases and controls, and between the subgroups of 
cases were conducted using nonparametric Mann-Whitney test, after testing for the normality 
of our parameters. The same test was performed to compare the levels of adipokines 
according to the case's clinical characteristics. Survival analysis was performed using the 
Kaplan-Meier method. To indicate statistical significance we used p value < 0.05.  
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3. Results 
3.1 Subjects characteristics 
As we can see in Table 1, we studied 69 controls and 111 Monoclonal Gammopathies (MG) 
patients, being 52 with MGUS, 20 with sMM and 30 with symptomatic MM. The mean age 
was similar in all four groups of subjects, being approximately 70 years. Controls were 
mainly females, and MG patients were mainly males. BM plasmocytosis and serum Ig 
concentration increased with disease progression, as they were lower in MGUS subjects (4.6 
± 2.2 % and 13.6 ± 5.5 g/L, respectively) and higher in the symptomatic MM patients (35.6 ± 
20.9% and 38.4 ± 27.0 g/L, respectively). 
In MGUS patients the monoclonal immunoglobulin was mainly of the IgG subtype (n = 35), 
being the rest IgA, IgM and biclonal IgM/IgG. sMM were mainly of the IgG and IgA subtype 
(n = 10 and n = 6, respectively) with only one individual with the IgM subtype, one with a 
biclonal component of IgA/IgG and two individuals with the light chain subtype. In what 
concerns the symptomatic MM subjects, 18 presented with IgG, 15 with IgA, five with light 
chain and one with IgD subtype. In what concerns the type of light chain, MGUS subjects had 
similar distribution between λ and κ light chains, as sMM and symptomatic MM patients 
produced mainly κ light chains. 
CRAB symptoms were defined as: serum calcium value higher than 11 mg/dL or more than 1 
mg/dL above the normal value (hypercalcemia),  serum creatinine value higher than 2 mg/dL 
(renal lesion), hemoglobin value lower than 10 g/dL or more than 2g/dL bellow the normal 
value (anemia) and  one or more osteolytic lesions in skeletal radiography, CT or PET-CT 
(bone lesion). Of the 39 MM patients, the main presenting symptoms were bone lesion and 
anemia (32 and 31 patients, respectively). Renal lesion and hypercalcemia only accounted for 
nine and eight patients, respectively. Finally, in what concerns the International Staging 
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System for Multiple Myeloma (ISS), the grand majority of them (n = 25) presented in the ISS 
stage III at the time of diagnosis, and the remaining 14, were evenly distributed between stage 
I and stage II. All this characteristics are summarized in Table 1. 
 
Table 1. Descriptive characteristics of cases and controls 
 Controls 
Cases 
MGUS sMM 
symptomatic 
MM 
n 69 52 20 39 
Male (n)/ Female (n) 28/41 32/20 9/11 18/21 
Age (mean ± SD) 70.9 ± 11.8 69.8 ± 10.1 72.4 ± 10.8 69.9 ± 10.8 
Plasma cells % (mean ± 
SD) 
- 4.6 ± 2.2 13.1 ± 6.9 35.6 ± 20.9 
Ig concentration g/L 
(mean ± SD) 
- 13.6 ± 5.5 26.4 ± 13.4 38.4 ± 27.0 
Type of heavy chain (n) 
IgA 
IgG 
IgM 
IgD 
IgM/IgG 
IgG/IgA 
Light chains 
- 
 
12 (23.1%) 
35 (67.3%) 
4 (7.7%) 
- 
1 (1.9%) 
- 
- 
 
6 (30%) 
10 (50%) 
1 (5%) 
- 
- 
1 (5%) 
2 (10%) 
 
15 (38.5%) 
18 (46.2%) 
- 
1 (2.5%) 
- 
- 
5 (12.8%) 
Type of light chain (n) 
λ 
κ 
κ/λ 
- 
 
25 (48.1%) 
27 (51.9%) 
- 
 
7 (35%) 
12 (60%) 
1 (5%) 
 
12 (30.8%) 
26 (66.7%) 
1 (2.5%) 
CRAB  symptoms (n) 
Hypercalcemia 
Renal lesion 
Anemia 
Bone lesion 
- - - 
8 (20.5%) 
9 (23.1%) 
31 (79.5%) 
32 (82.1%) 
ISS (n) 
I 
II 
III 
- - - 
 
7 (17.9%) 
7 (17.9%) 
25 (64.1%) 
n - Number of cases;  SD - standard deviation; % - percentage 
 
3.2 Evaluation of adipokines levels in patients and controls 
We first compared the levels of adipokines in PB of all the cases (MG patients all together in 
the same group) with those observed in controls (Table 2). We detected significant higher 
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levels of leptin and resistin in PB of MG patients (13.2 ng/mL and 9.49 ng/mL, respectively) 
compared with controls (7.95 ng/mL and 7,42 ng/mL, respectively). No significant 
differences were found in what regards to adiponectin in this analysis.  
In order to explore if there were any differences if we considered each subtype of MG 
separately, we compared control individuals with each MG subtype and between the different 
subtypes of MG patients (Table 3 and Figure 1A, B). 
 
 
 
In the PB samples, adiponectin was significantly higher in the MGUS patients when 
compared with the controls (p = 0.012) and with symptomatic MM subjects (p = 0.04). 
MGUS patients also showed higher levels of resistin than the controls (p = 0.001). On the 
other hand, we found that sMM was associated with increased PB leptin when compared with 
controls (p = 0.001), MGUS (p = 0.012)  and symptomatic MM (p = 0.043). TNF-α levels 
were also increased in sMM compared with MGUS individuals (p = 0.034). Symptomatic 
MM patients had higher levels of resistin than controls (p = 0.014). Although not statistically 
significant, symptomatic MM individuals tended to have higher levels of MCP-1 than MGUS 
judging by the IQR (Table 3).  
In the BM samples, the results were somewhat overlapping with those from the PB samples. 
We found significant increase in leptin levels of sMM subjects compared with MGUS (p = 
Table 2. Levels of adiponectin, leptin and resistin in the PB of controls and MG subjects 
 
Controls 
n = 69 
MG 
Adiponectin μg/mL 6.36 (5.65) 
6.92 (11.85) 
n = 110 
Leptin ng/mL 7.95 (13.64) 
13.2 (13.52) 
a
 
n = 111 
Resistin ng/mL 7.42  (5.13) 
9.49 (9.73) 
a
 
n = 111 
Results in median (IQR); n - Number of cases;  a - p < 0.01  
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0.003) and symptomatic MM patients (p = 0.021). The BM levels of resistin and MCP-1 in 
symptomatic MM patients tended for higher levels comparing with MGUS judging by their 
respective IQR, even though it was not statistically significant. PB and BM results are 
illustrated in Figure 1A and B, respectively. 
 
  
Table 3. Levels of adipokines in the PB and BM of controls, MGUS, sMM and symptomatic MM subjects 
  
Controls 
n = 69 
MGUS sMM 
symptomatic 
MM 
P
er
ip
h
er
a
l 
b
lo
o
d
 
Adiponectin 
μg/mL 
6.36 (5.65) 
8.43 (14.14)
a
 
n = 51 
6.73 (10.59) 
n = 20 
6.32 (7.67) 
n = 39 
Leptin ng/mL 7.95 (13.64) 
10.48 (11.14) 
n = 52 
17.9 (16.83)
b
 
n = 20 
13.53 (14.01) 
n = 39 
Resistin ng/mL 7.42 (5.13)
c
 
10.74 (8.51) 
n = 52 
8.45 (5.44) 
n = 20 
8.8 (13.99) 
n = 39 
MCP-1 pg/mL - 
193.09 (181.0) 
n = 31 
729.8 (770.98) 
n = 9 
148.59 (531.75) 
n =28 
TNF-α pg/mL - 
7.0 (4.24) 
n = 21 
11.86 (3.9)
d
 
n = 7 
8.73 (8.59) 
n = 14 
B
lo
o
d
 m
a
rr
o
w
 
Adiponectin 
μg/mL 
- 
16.68 (46.4) 
n = 52 
8.34 (19.92) 
n = 20 
9.52 (17.36) 
n = 37 
Leptin ng/mL - 
13.34 (12.31) 
n = 52 
23.35 (10.73)
c
 
n = 20 
15.38 (14.21) 
n = 37 
Resistin ng/mL - 
34.02 (47.89) 
n = 52 
21.82 (36.81) 
n = 20 
25.2 (58.52) 
n = 37 
MCP-1 pg/mL - 
343.52 (271.95) 
n = 31 
738.74 (795.24) 
n = 10 
390.9 (708.57) 
n = 25 
TNF-α pg/mL - 
8.45 (10.22) 
n = 21 
11.0 (7.24) 
n = 7 
11.3 (10.32) 
n = 14 
Results in median (IQR);  n - Number of cases;    
(a) - p < 0.05, different from controls and symptomatic MM  
(b) - p < 0.01, different from controls, and p < 0.05, different from MGUS and symptomatic MM  
(c) - p < 0.01, different from MGUS, and  p < 0.05, different from symptomatic MM 
(d) - p < 0.05, different from MGUS 
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3.3 Correlation of adipokines levels with patient's subtype of paraprotein 
Results regarding the type of heavy chain secreted are fully described in Table 4, for all 
subgroups of patients. Figure 2A and B illustrates the results for symptomatic MM patients 
in the PB and BM samples, respectively. 
In the PB samples of symptomatic MM patients, when comparing the IgA patients with the 
IgG subtype, we could not detect any significant difference between them. However, in 
patients with IgA subtype we observe a tendency for higher levels of adiponectin compared 
with other Ig subtypes (p = 0.055). On the other hand, when we looked for differences in MM 
patients between these two heavy chain subtypes and light-chain (LC), we found that patients 
with LC had higher levels of adiponectin than IgA and IgG subtypes (p = 0.013 and p = 
0.006, respectively), and lower levels of leptin when compared only with the IgG subtype (p = 
0.006). Furthermore, LC MM patients had a tendency for higher TNF-α levels, but the results 
didn't show statistical significance. 
Once again, the results in the BM samples of these individuals were overlapping with those 
from the PB samples. However, we found more significant differences in the BM. Between 
the IgA and the IgG subtype, MCP-1 levels were higher in the later (p = 0.018). Adiponectin  
1A 1B 
Fig. 1 - Adipokines levels in PB (A) and BM (B) of controls, MGUS, sMM and symptomatic MM individuals.  
# - p < 0.05; ## - p < 0.01; o and * - outliers 
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levels were again higher in the LC subtype when compared with the IgG (p = 0.007) and IgA 
patients subtypes (p = 0.01).Moreover, we observed higher levels of TNF-α than the IgG MM 
subjects (p = 0.037). In the same individuals, we also found lower levels of leptin than IgG (p 
= 0.005) and IgA MM individuals (p = 0.026), as well as lower levels of resistin compared 
only with the IgG subtype (p = 0.009). Because we only had one case of IgD MM subtype, we 
did not test if there were any differences with the other Ig subtypes. We performed the same 
statistical analysis for MGUS and sMM subjects, but we didn't find any significant difference.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2A 2B 
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We also analyzed the differences in the pattern of adipokines according to the type of light 
chain. However, the secretion of adipokines does not seem to be dependent from the type of 
light chain that is produced in symptomatic MM patients, because no significant differences 
were found. By performing the same tests on MGUS and sMM subjects, we observed that 
MGUS subjects who produced κ light chains had higher BM MCP-1 levels than those who 
produced λ light chains (p = 0.02). Results regarding adipokines levels according to the type 
of light chain produced are fully described in Table 5. 
  
2A 2B 
Fig. 2 - Adipokines levels in the PB (A) and BM (B) of symptomatic MM individuals according to the type of 
heavy chain secreted.  
# - p < 0.05; ## - p < 0.01; o and * - outliers 
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3.4 Analysis of adipokines levels according to CRAB symptoms 
Firstly we went to see if there was any difference between those patients who had 
hypercalcemia, and those who had not (Table 6). Despite the tendencies for different levels in 
all adipokines, the only statistically significant difference detected between those who had 
hypercalcemia and those who had not, were the levels of leptin in both PB and BM, being 
lower in the patients with hypercalcemia as represented in Table 6 (PB- p = 0.037; BM - p = 
0.04). 
Table 6. Adipokines levels according to absence or presence of hypercalcemia 
 Absence Presence 
P
er
ip
h
er
a
l 
b
lo
o
d
 
Adiponectin μg/mL 
4.62 (7.11) 
(n = 31) 
9.59 (13.11) 
(n = 8) 
Leptin ng/mL 
14.1 (13.81) 
a
 
(n = 31) 
7.23 (9.25) 
(n = 8) 
Resistin ng/mL 
9.2 (15.61) 
(n = 31) 
6.29 (8.4) 
(n = 8) 
MCP-1 pg/mL 
126.16 (469.25) 
(n = 24) 
462.57 (922.59) 
(n = 4) 
TNF-α pg/mL 
6.34 (9.09) 
(n = 11) 
11.0 
(n = 3) 
B
lo
o
d
 m
a
rr
o
w
 
Adiponectin μg/mL 
9.35 (13.33) 
(n = 30) 
22.78 (59.59) 
(n = 7) 
Leptin ng/mL 
16.97 (13.79) 
a
 
(n = 30) 
9.23 (13.33) 
(n = 7) 
Resistin ng/mL 
32.32 (62.51) 
(n = 30) 
17.9 (22.02) 
(n = 7) 
MCP-1 pg/mL 
377.8 (584.04) 
(n = 22) 
1040.17 
(n = 3) 
TNF-α pg/mL 
10.65 (7.81) 
(n = 11) 
12.38 
(n = 3) 
Results in median (IQR) when available;  n - Number of cases; (a) - p < 0.05;  
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No significant differences were found in the levels of adipokines in both PB and BM between 
patients who had renal lesion and those who had not, as described in Table 7. However, PB 
resistin showed a tendency for higher levels in individuals who presented with renal lesion 
than those who did not (p = 0.062).  
Table 7. Adipokines levels according to absence or presence of renal lesion 
 Absence Presence 
P
er
ip
h
er
a
l 
b
lo
o
d
 
Adiponectin μg/mL 
4.82 (7.24) 
(n = 30) 
6,77 (14.06) 
(n = 9) 
Leptin ng/mL 
13.42 (12.03) 
(n = 30) 
14.1 (62.89) 
(n = 9) 
Resistin ng/mL 
8.25 (10.84) 
(n = 30) 
18.44 (46.94) 
(n = 9) 
MCP-1 pg/mL 
144.05 (500.02) 
(n = 22) 
158.05 (880.04) 
(n = 6) 
TNF-α pg/mL 
6.67 (8.37) 
(n = 12) 
13.63 
(n = 2) 
B
lo
o
d
 m
a
rr
o
w
 
Adiponectin μg/mL 
9.36 (16.8) 
(n = 28) 
10.05 (40.78) 
(n = 9) 
Leptin ng/mL 
14.81 (14.08) 
(n = 28) 
23.4 (61.84) 
(n = 9) 
Resistin ng/mL 
27.88 (71.08) 
(n = 28) 
25.2 (42.10) 
(n = 9) 
MCP-1 pg/mL 
390.9 (665.31) 
(n = 19) 
403.7 (904.23) 
(n = 6) 
TNF-α pg/mL 
11.05 (16.52) 
(n = 12) 
11.77 
(n = 2) 
Results in median (IQR) when available;  n - Number of cases 
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Results shown in Table 8 represents the levels of adipokines in symptomatic MM patients 
related to the presence or absence of anemia. We found that MM patients with anemia had 
statistically significant higher levels of BM MCP-1, than those without this symptom (p = 
0.032). In the PB, we observed the same tendency, but with no statistical significance (p = 
0.057). We did not detect any differences in the levels of other adipokines, neither in the PB, 
nor in the BM.  
Table 8. Adipokines levels according to absence or presence of anemia 
 Absence Presence 
P
er
ip
h
er
a
l 
b
lo
o
d
 
Adiponectin μg/mL 
4.83 (11.03) 
(n = 8) 
6.7 (7.69) 
(n = 31) 
Leptin ng/mL 
12.94 (7.86) 
(n = 8) 
13.9 (14.8) 
(n = 31) 
Resistin ng/mL 
7.31 (16.8) 
(n = 8) 
8.8 (13.29) 
(n = 31) 
MCP-1 pg/mL 
100.62 (20.10) 
(n = 4) 
203.46 (576.26) 
(n = 24) 
TNF-α pg/mL 
2.89 
(n = 1) 
10.46 (8.64) 
(n = 13) 
B
lo
o
d
 m
a
rr
o
w
 
Adiponectin μg/mL 
7.19 (16.21) 
(n = 8) 
10.05 (18.49) 
(n = 29) 
Leptin ng/mL 
14.15 (5.46) 
(n = 8) 
18.7 (15.15) 
(n = 29) 
Resistin ng/mL 
57.73 (127.59) 
(n = 8) 
20.02 (47.89) 
(n = 29) 
MCP-1 pg/mL 
140.16 (112.72) 
(n = 4) 
438.1 (676.37) 
a 
(n = 21) 
TNF-α pg/mL 
6.50 
(n = 1) 
11.45 (12.59) 
(n = 13) 
Results in median (IQR) when available;  n - Number of cases; (a) - p < 0.05  
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Finally, we observed a statistical significant differences in leptin PB levels between patients 
who had bone lesions and those who had not, as the later ones had lower  levels (p = 0.05), 
similar to what we have seen when we looked for associations with hypercalcemia (see Table 
6 above). Patients without bone lesion showed the same tendency for BM leptin levels. The 
levels of other adipokines were not different whether if the patient had bone lesion or not. 
Results are described in Table 9. 
Table 9. Adipokines levels according to absence or presence of bone lesion 
 Absence Presence 
P
er
ip
h
er
a
l 
b
lo
o
d
 
Adiponectin μg/mL 
10.46 (6.91) 
(n = 6) 
4.82 (6.06) 
(n = 32) 
Leptin ng/mL 
24.18 (83.51) 
(n = 6) 
12.83 (12.46) 
a
 
(n = 32) 
Resistin ng/mL 
7.98 (20.86) 
(n = 6) 
9.0 (15.45) 
(n = 32) 
MCP-1 pg/mL 
311.1 (743.37) 
(n = 5) 
126.76 (481.73) 
(n = 23) 
TNF-α pg/mL 
9.28 (8.3) 
(n = 4) 
8.40 (14.45) 
(n = 10) 
B
lo
o
d
 m
a
rr
o
w
 
Adiponectin μg/mL 
16.15 (30.77) 
(n = 6) 
9.35 (16.2) 
(n = 30) 
Leptin ng/mL 
24.32 (70.84) 
(n = 6) 
14.81 (14.29) 
(n = 30) 
Resistin ng/mL 
31.2 (152.96) 
(n = 6) 
24.19 (49.54) 
(n = 30) 
MCP-1 pg/mL 
438.1 (676.06) 
(n = 5) 
381.79 (711.24) 
(n = 20) 
TNF-α pg/mL 
10.32 (19.27) 
(n = 4) 
11.3 (10.32) 
(n = 10) 
Results in median (IQR);  n - Number of cases; (a) - p = 0.05;  
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3.5 Analysis of adipokines according to the ISS stage 
The levels of adipokines according the ISS prognostic system are summarized in Table 10. 
As we can observe, in general, we observed in both PB and BM patients with higher ISS 
stages, a tendency for an increase in pro-inflammatory adipokines, being the differences for 
resistin PB levels statistically higher in stage III patients comparing with those in stage I (p = 
0.006). Interestingly, we found the opposite tendency in the BM of the same group of 
individuals, but without statistical significance (p = 0.378) (Table 10 and Fig. 3).  
Table 10. Adipokines levels according to the ISS  
 I II III 
P
er
ip
h
er
a
l 
b
lo
o
d
 
Adiponectin μg/mL 
6.88 (6.74) 
(n = 7) 
7.65 (8.57) 
(n = 7) 
5.19 (8.74) 
(n = 25) 
Leptin ng/mL 
12.35 (12.95) 
(n = 7) 
14.64 (23.18) 
(n = 7) 
13.9 (13.95) 
(n = 25) 
Resistin ng/mL 
5.81 (3.37) 
(n = 7) 
7.36 (11.2) 
(n = 7) 
15.2 (20.71)
a
 
(n = 25) 
MCP-1 pg/mL 
109.59 (420.2) 
(n = 4) 
144.05 (284.77) 
(n = 6) 
203.46 (658.01) 
(n = 18) 
TNF-α pg/mL 
5.33 
(n = 1) 
3.42 (18.12) 
(n = 5) 
10.73 (8.57) 
(n = 8) 
B
lo
o
d
 m
a
rr
o
w
 
Adiponectin μg/mL 
9.34 (20.59) 
(n = 6) 
9.52 (16.74) 
(n = 7) 
9.78 (18.99) 
(n = 24) 
Leptin ng/mL 
14.03 (9.15) 
(n = 6) 
13.8 (12.16) 
(n = 7) 
20.26 (15.15) 
(n = 24) 
Resistin ng/mL 
49.98 (256.31) 
(n = 6) 
61.09 (126.06) 
(n = 7) 
22.95 (26.23) 
(n = 24) 
MCP-1 pg/mL 
154.18 
(n = 3) 
381.79 (217.46) 
(n = 6) 
484.53 (768.41) 
(n = 16) 
TNF-α pg/mL 
10.65 
(n = 1) 
6.5 (18.14) 
(n = 5) 
11.92 (13.68) 
(n = 8) 
Results in median (IQR) when available;  n - Number of cases; (a) - p < 0.01, different from stage I  
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3.6 Survival curves 
We investigated if the overall survival in symptomatic MM patients was affected by any kind 
of adipokines pattern, using the Kaplan-Meier method. During a 3-year follow-up of these 
patients, 25 out of 39 died, presenting an overall survival of 12.4 ± 8.9 months. From these 25 
patients, seven died of progressive disease, six died of infectious disease and three died of 
cardiovascular disease. The causes of death of the other patients were not clarified.  
We divided the symptomatic MM patients in two groups, using cut-off values based on the 
mean levels of each adipokine, in both PB and BM (Group 1 - respective adipokine levels < 
cut-off; Group 2 - respective adipokine levels ≥ cut-off). Cut-off values used are shown in 
Table 11. 
We found that, patients with PB adiponectin levels lower than 8.6 μg/mL, (group 1) had a 
better mean survival than those with higher levels (15.1 ± 2.3 months vs 8.3 ± 2.3 months - p 
= 0.018). When we looked for the same differences in the overall survival, taking into account 
the BM adiponectin levels (mean = 18.9 μg/mL), although group 1 still had a better overall 
survival (12.5 months vs 8.8 months), it was not statistically significant (p = 0.351) (Fig. 4A). 
3A 3B 
Fig. 3 - Resistin levels in PB (A) and BM (B) of MM individuals according to the ISS stage.  
## - p < 0.01; o  - outliers 
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Additionally, we observed that BM leptin levels (mean = 26.7 ng/mL) affected overall 
survival. Group 1 had a mean overall survival of 13.1 ± 2.0 months and group 2 had 2.8 ± 1.0 
months (p = 0.005). When we took into account the PB leptin levels, overall survival also 
tended to be superior in group 1 (13.9 ± 1.9 months vs  6.3 ± 4.1 months), but without 
statistical significance (p = 0.074) (Fig. 4B). 
The PB and BM levels of other adipokines did not influence the survival of symptomatic MM 
patients (results not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
4A 
4B 
Fig. 4 - Overall survival of symptomatic MM individuals according to adiponectin (A) and leptin (B) levels 
in the PB and BM. 
Blue line - Group 1;  Green line - Group 2 
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Table 11. Cut-off values used for each adipokine in PB and BM of symptomatic MM patients 
 Peripheral Blood Bone marrow 
Adiponectin μg/mL 8.6  18.9 
Leptin ng/mL 24.2 26.7 
Resistin ng/mL 23.1 73.9 
MCP-1 pg/mL 342.4 496.1 
TNF-α pg/mL 11.0 13.4 
Cut-off values are expressed in mean levels  
The Role Of Adipokines In Monoclonal Gammopathies 
 
35 
 
4. Discussion and Conclusion 
Adipokines display an important role in several physiological functions in the organism. 
Obesity, is related with a low-grade inflammation, since there is a decrease in adiponectin and 
an increase in pro-inflammatory adipokines with an oncogenic potential 
(18,29)
. Although it is 
well documented that, obesity increase the risk for some types of solid tumors, most of the 
studies, showing that adipokines participate in this relationship, are in vitro studies 
(17)
. 
However, the role of adipokines in hematological malignancies is poorly understood, and in 
what regards MM, only a few studies were undertaken.  
Our results show that in PB MG patients have higher levels of leptin and resistin than control 
individuals. The analysis of the adipokines PB levels in each different MG subgroups, showed 
that MGUS patients had higher levels of adiponectin than symptomatic MM individuals, as 
well as lower levels of TNF-α. Also, sMM patients had higher levels of leptin compared with 
controls, MGUS and symptomatic MM patients. PB resistin levels were higher in both MGUS 
and symptomatic MM patients than control individuals. MCP-1 tended for higher levels in the 
symptomatic MM group comparing with MGUS. In the BM, the sMM also presented with 
higher levels of leptin than MGUS and symptomatic MM patients. Adiponectin levels tended 
as well to be lower in the later stages of the disease. Resistin and MCP-1 were higher in the 
symptomatic MM subgroup of individuals. As the BM levels appears to have the same pattern 
of the PB, this indicates that the PB levels reflects the levels in the BM microenvironment.  
As adipokines can exhibit anti- and pro-inflammatory properties, these results suggest that in 
the progression from from MGUS to MM, deregulation of the production of adipokines 
creates a pro-inflammatory state in the BM microenvironment, which can contribute to the 
carcinogenic process. 
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In what concerns adiponectin, Hoffman et al. 
(30)
 observed an inverse association between 
MM risk and adiponectin plasma levels. Moreover, Dalamaga et al. 
(31)
, also reported that 
MM individuals had lower serum levels of adiponectin. Our results are in agreement with 
both of these studies. Adiponectin is an anti-inflammatory adipokine that may exert its effects 
through inhibition of the NF-κB pathway. This in turn, suppresses production of various 
cytokines such as IL-6 and TNF-α, which are important growth factors for MM cells (12–
14,32,33)
. Adiponectin may as well increase the production of anti-inflammatory cytokine IL-10 
(24)
. It is possible that adiponectin may act as a protective factor in MGUS individuals and as a 
marker of progression from MGUS to MM. A study conducted by Fowler et al. 
(34)
 discovered 
that, host-derived adiponectin reduced tumor burden, increased survival of myeloma-bearing 
mice and prevented bone disease. This gives adiponectin some potential as a novel biomarker 
and therapeutic target.  
Leptin is an adipokine that regulates caloric intake and energy homeostasis. Other studies 
found that MM individuals presented with higher plasma levels of leptin than controls 
(31,35–
38)
. Recently, it was shown that MM cells express leptin receptors, and that blockage of those 
receptors leads to a decrease in the DNA synthesis 
(27)
. Reseland et al., in 2009, reported that 
leptin induced the expression of several genes involved in cell growth, survival and signaling 
in two myeloma cell lines 
(35)
. As stated before, the adipocytes are often forgotten in the 
studies of MM. Reseland's and our results suggest that adipocytes may have a role in 
pathogenesis of MM, since they are the major producers of leptin. Interestingly, in our study, 
leptin levels were higher in the sMM subgroup, rather than in the symptomatic MM subgroup. 
It could be due to the fact that, during the disease development, BM adipocytes tend to 
disappear, suggesting that the role of BM adipocytes may be restricted to the initial stages of 
the disease, before a remodeling of the BMM has occurred 
(27)
. This can mean that the 
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maximum levels of leptin are produced during sMM phase, before the progression to MM, 
when symptoms, like bone lesions, change the BMM.  
Our results suggest that resistin contributes to the creation of a pro-inflammatory state in the 
BM.  Two other studies 
(36,37)
 focusing on leptin and resistin serum levels didn't found any 
significant differences between MM patients and controls. Interestingly, another study 
(31)
 
observed significant lower serum levels of resistin in MM patients compared with controls. 
The authors reported that this finding could be possibly due to a compensatory response of the 
resistin pathway to the upregulation of other inflammatory and proliferative factors. PB 
resistin levels in our study, where higher in MGUS and symptomatic MM patients than in 
controls.  
Resistin is an adipokine related with insulin-resistance and activation of inflammatory 
processes. Whereas in mice, resistin is produced mainly in the adipocytes, in humans it is 
produced mainly by macrophages and monocytes 
(18)
. This promotes the production of IL-6 
and TNF-α, which are important growth factors for MM cells (12–14,18,33).  To our knowledge, 
there are no studies showing that in MM resistin prodution, is mainly due to BM 
macrophages. 
Additionally, we observed that MCP-1 tended to be higher in PB and BM in patients in the 
later stages of the disease, when compared with MGUS patients. In what regards to TNF-α, 
we only found higher levels in the PB of sMM patients compared with MGUS subgroup. 
MCP-1 is a potent chemoattractant that acts through CCR2 receptor, which is also expressed 
in MM cells 
(39)
, resulting in enhanced migration of the malignant clone. This makes MCP-1 
an attractive therapeutic target for MM 
(39)
. In fact, blockage of CCR2 receptor and 
neutralization of MCP-1, -2 and -3 significantly reduced migration of human MM cells to 
marrow stromal cell-conditioned medium 
(39)
. TNF-α acts not only as a growth factor, but also 
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upregulates the production of MCP-1 by the BM stromal cells. We did not find any other 
studies measuring MCP-1 and TNF-α levels in MM patients. 
According with Ig subtype, namely between the IgA and IgG symptomatic MM patients, we 
only found higher levels of BM MCP-1 in those who produced IgG heavy chains. However, 
we observed higher PB and BM levels of adiponectin and lower levels of BM leptin of those 
who only produced light chains relatively to those who produced IgA or IgG heavy chains. 
Additionally, MM patients with light chains were associated with lower leptin PB levels and 
lower resistin and TNF-α BM levels than patients with IgG subtype. In what regards the type 
of light chain secreted, we only observed higher BM MCP-1 levels in κ light chain MGUS 
patients. 
The type of immunoglobulin that is secreted can affect the outcome of patients. For example, 
the IgA subtype was associated with more severe anemia, and with lower overall survival 
(40).
 
Also the LC subtype is associated with higher incidence of renal lesion. However, in one 
study, overall survival was comparable to the IgG MM patients 
(40)
. Furthermore, one study 
showed a positive correlation between serum levels of leptin and IgG levels in MM patients 
(36)
. Our results suggest that, given the differences especially between the light chain and 
IgG/IgA subtype, the adipokines may have different roles in the different MM subtypes, as 
they could participate in the immunological changes underlying the pathogenesis of MM. 
Some features of MGUS are referred as risk factors for progression to MM. For MGUS, non-
IgG subtype is associated with higher progression rates to MM, especially when associated 
with an M-protein concentration higher than 1,5 g/dL and an abnormal free-light chain 
ratio
(7)
. However, we did not find any differences in what concerns the type of heavy chain 
secreted by MGUS patients.  
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The presence of CRAB symptoms is required to define the diagnosis of symptomatic MM. In 
our study we observed higher levels of leptin in the PB and BM of patients without 
hypercalcemia and without bone lesion. Leptin stimulates bone formation through promotion 
of osteoblast differentiation, bone mineralization and modification of osteoclast 
differentiation 
(41)
. It is possible that the high levels of leptin in MM act as protective factor 
for bone disease, and therefore, prevent the occurrence of these symptoms. 
We also found higher levels of BM MCP-1 in patients who developed anemia. Anemia in 
MM is present in about 73% of the patients at diagnosis (5). The origin of the anemia is 
multifactorial and complex, but it is mainly due to the expansion of malignant cells in the 
BM. As MCP-1 acts as a chemoattractant to MM cells to the BM, our results suggest that 
MCP-1 may contribute to anemia related with BM infiltration.  
The International Staging System (ISS) for MM is currently used for disease staging. It takes 
into account albumin and β2-microglobulin serum levels. Our results show that there is a 
significant increase in PB resistin levels from patients in stage I to patients in stage III. 
Interestingly, we found the opposite tendency for BM resistin. We could not find any 
explanation for this finding. As resistin, in humans, is mainly produced by macrophages, it 
could be interesting to see if there are any differences in the BM macrophages of MM patients 
in the different stages of the ISS. However, our results suggest that higher ISS stages tend to 
be associated with higher levels of pro-inflammatory adipokines. Comparing patients 
stratified according with the Durie-Salmon staging system, Dalamaga et al. 
(31)
 found that  
higher stages tended to present higher levels of leptin, and Esheba et al. 
(36)
 found that stage II 
patients had higher leptin levels than those in stage I.  
There is some controversy in what regards the ISS, since it was established using data from 
patients who did not had access to novel therapeutics agents 
(42)
, meaning that this staging 
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system could fail to predict correctly the prognosis of some patients. One study suggested the 
creation of a new staging system consisting in the presence of anemia and plasmocytoma 
(42)
.  
With the introduction of novel therapeutics, MM overall 5-year relative survival increased 
from 28,8% to 34,7%, and 10-year relative survival from 11,1% to 17,4% 
(43)
. By analyzing 
the impact of the levels of adipokines in overall survival of symptomatic MM patients, we 
observed that high PB adiponectin and BM leptin levels were associated with significantly 
reduced overall survival. As sMM and symptomatic MM patients had lower levels of 
adiponectin compared with MGUS, it is possible that the decrease in the levels of adiponectin 
act as marker of progression to MM, and, during the disease, as a protective factor.  
In summary, as disease progresses from MGUS to symptomatic MM, there is a decrease in 
the levels of anti-inflammatory adipocytokine adiponectin, and an increase in pro-
inflammatory adipokines, which could contribute to the mielomagenesis process through the 
generation of a pro-inflammatory microenvironment. There seems to exist different roles for 
adipokines levels according to the type of paraprotein produced, as MM patients producing 
different subtypes of Igs, have different patterns of adipokines production. Patients with 
symptomatic MM without bone lesion and hypercalcemia have higher levels of leptin, which 
could reflect the ability of promoting osteoblastic differentiation and bone mineralization. 
Moreover, MCP-1 was higher in patients presenting with anemia, which could mean that 
MCP-1 plays a role in BM infiltration by malignant cells and development of anemia.  
Resistin levels were higher in the PB of MM patients in stage III, and lower in the BM of the 
same individuals. Additionally, high levels of adiponectin and leptin affected patient's overall 
survival, which could translated that these adipokines could have a potential prognostic value. 
As MM remains an incurable disease and with poor prognosis, all efforts to better understand 
the pathogenesis of MM are of major importance. Not only it will allow us to clarify the 
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mechanisms of the disease, but it will also allow us to discover new therapeutic targets and 
create groups of risk for the disease, with the objective of improving the prognosis of the 
patients. However, further studies are needed to investigate the importance of the adipokines 
in MM and to clarify its therapeutic and prognostic value in the clinical practice.  
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